Brief Reports
Copyright ©The Author(s) 2001.
World J Gastroenterol. Jun 15, 2001; 7(3): 411-414
Published online Jun 15, 2001. doi: 10.3748/wjg.v7.i3.411
Table 1 Responses to treatment at the end of therapy n (%)
T-a1 (n = 18)
IFN-α (n = 33)
HC (n = 30)
(after 6 mo of follow-up)
ALT normalization7 (38.9)16 (48.5)5 (16.7)
HBV DNA-negative10 (55.6)b22 (66.7)b2 (6.7)
ALT normal/HBV DNA and HBeAg-negative6 (33.3)15 (45.5)b1 (3.3)
Table 2 Responses to treatment at the end of follow-up n (%)
T-a1 (n = 18)
IFN-α (n = 33)
HC (n = 30)
(after 12 mo of follow-up)
ALT normalization11 (61.1)a10 (30.3)3 (10)
HBV DNA-negative13 (72.2)ab13 (39.4)b2 (6.7)
ALT normal/HBV DNA and HBeAg-negative10 (55.6)ab9 (27.3)1 (3.3)